Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have transformed the treatment landscape in front-line and recurrent high-grade serous ovarian cancer. Maintenance strategies with PARPi have been assessed in randomized phase III trials in ovarian cancer; switch maintenance in the case of olapa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Gynecol Cancer
Autors principals: Madariaga, Ainhoa, Bowering, Valerie, Ahrari, Soha, Oza, Amit M, Lheureux, Stephanie
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7398227/
https://ncbi.nlm.nih.gov/pubmed/32276934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ijgc-2020-001288
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars